potential indications for glp-1 receptor agonists keep expanding in Cardiovascular Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies GLP1-GIP receptor co-agonists: a promising

Zobel EH, Ripa RS, von Scholten BJ, Rotbain Curovic V, Kjaer A, Hansen TW, et al

Both the pharmacovigilance findings and the case series indicated that liraglutide and dulaglutide were the leading suspected GLP-1 RAs, and pharmacovigilance analysis showed that exenatide had the highest number of ICSRs associated with AP

Also, the hypothalamus's GIP receptor signaling controls body weight and appetite [150]

doi:10.1186/s12929-017-0379-z 154

in clinical use, the best-known GIP-related medication is tirzepatide, sold as Mounjaro for type 2 diabetes and Zepbound for weight management, and it is called a dual GIP/GLP-1 receptor agonist because it acts on both pathways